Clinical significance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck
| Autor: | Young-Ik Son, Yong Chan Ahn, Myung Hee Chang, Y.S. Park, K. Park, Jeong-Hwan Baek, Hyun Jung Jun, M-J. Ahn, Young-Hyeh Ko, Han-Sin Jeong |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Cancer Research
medicine.medical_specialty biology business.industry Growth factor medicine.medical_treatment Insulin-Like Growth Factor Receptor Insulin-like growth factor-binding protein Endocrinology Oncology Growth factor receptor Internal medicine Cancer cell Cancer research medicine biology.protein Immunohistochemistry Clinical significance business Survival rate |
| Zdroj: | Journal of Clinical Oncology. 27:6036-6036 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 6036 Background: Type 1 insulin-like growth factor receptor (IGF-1R) plays an important role in the growth and apoptosis of cancer cell. The activities of IGF-1R are modulated by a family of high-affinity insulin-like growth factor binding proteins (IGFBPs), of which IGFBP-3 is the major serum carrier protein. The expression and significance of IGF-1R and IGFBP-3 in squamous cell carcinoma of the head and neck (SCCHN) is unknown. Methods: This study explored immunohistochemical expression of IGF-1R and IGFBP-3 in tumor samples from 131 patients with surgically resected SCCHN. Results: The positive expression of IGF-1R and IGFBP-3 was observed in 96 (73.3%) and 117 (89.3%) patients. There were no significant differences in baseline characteristics between the positive and negative expressed groups of IGF-1R and IGFBP-3. With the median follow up of 53.5 months, 3 year progression free (PFS) and overall (OS) survival rate was 64.0% and 72.9%, neither IGF-1R nor IGFBP-3 expression had prognostic values in the whole cohort. Thirty-seven (67.3%) of 55 stage IV patients demonstrated IGF-1R positivity. The subgroup analysis of in stage IV patients showed the poor PFS ( = 0.029) and OS (pp = 0.025) in IGF-1R positive groups. In a multivariate analysis using IGF-1R expression and other clinicopathological parameters, the IGF-1R expression was remained as an independent factor for PFS (p = 0.037, HR = 2.816, 95% C.I. 1.065 - 7.446) and OS (p = 0.034, HR = 3.169, 95% C.I. 1.089 - 9.225). Conclusions: Our work exhibited that IGF-1R expression is frequent in SCCHN patients and related with poor survival in advanced stage, this could support the attempts using the IGF-1R inhibitor for treatment of SCCHN. No significant financial relationships to disclose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|